Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
This is a multi-center, open label, non-randomized Phase 1 study, to be conducted in two parts, Part A, and Part B. Part A is the dose escalation phase for evaluating the safety and tolerability profile of PRN1371, a FGFR 1-4 Kinase inhibitor. Part B is the Cohort Expansion phase to further evaluate safety and tolerability, preliminary activity, PK, and PD in patients with FGFR genetic alterations.
Critère d'inclusion
- Solid Tumors